Gastrointestinal endoscopy · 2026
Antibiotic Prophylaxis for Peroral Cholangioscopy: A Systematic Review and Meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alsaleh Tareq, Fawwaz Baha, Almujarkesh Mohamad Khaled, Akram Hamza, Jose Calvin, Shafique Nouman, Malik Amna S, Arain Mustafa, George John
Аннотация
BACKGROUND AND AIMS: Antibiotic prophylaxis is commonly used before ERCP with peroral cholangioscopy, but supporting evidence is limited. We evaluated whether prophylaxis reduces post-procedural cholangitis after cholangioscopy.
METHODS: We searched Embase, PubMed, Web of Science, and Scopus through February 2026 for studies reporting cholangitis stratified by prophylaxis exposure. Random-effects meta-analysis was used to pool risk ratios.
RESULTS: Six studies including 2,531 patients and 2,575 procedures were included. The pooled cholangitis rate was 3.0% with prophylaxis and 7.8% without prophylaxis. Antibiotic prophylaxis was associated with lower cholangitis risk (risk ratio, 0.46; 95% confidence interval, 0.22-0.95; I2 = 40.4%), although the estimate was of borderline significance and not robust to individual study removal. Certainty of evidence was very low.
CONCLUSIONS: Antibiotic prophylaxis was associated with a reduction in post-cholangioscopy cholangitis that was of borderline significance and sensitive to individual studies. Prospective studies are needed to define optimal patient selection and regimens.
METHODS: We searched Embase, PubMed, Web of Science, and Scopus through February 2026 for studies reporting cholangitis stratified by prophylaxis exposure. Random-effects meta-analysis was used to pool risk ratios.
RESULTS: Six studies including 2,531 patients and 2,575 procedures were included. The pooled cholangitis rate was 3.0% with prophylaxis and 7.8% without prophylaxis. Antibiotic prophylaxis was associated with lower cholangitis risk (risk ratio, 0.46; 95% confidence interval, 0.22-0.95; I2 = 40.4%), although the estimate was of borderline significance and not robust to individual study removal. Certainty of evidence was very low.
CONCLUSIONS: Antibiotic prophylaxis was associated with a reduction in post-cholangioscopy cholangitis that was of borderline significance and sensitive to individual studies. Prospective studies are needed to define optimal patient selection and regimens.